Market cap
$302 Mln
Revenue (TTM)
$807 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -4.84 | -10.51 | -3.16 | 4.89 | 4.02 |
| EBIT | -28.33 | 88.30 | 77.09 | 17.84 | -1.43 |
| Net Profit | -26.69 | 86.93 | 71.51 | 15.64 | -1.71 |
| EPS | -25.22 | 87.25 | 72.02 | 17.12 | 2.40 |
| Book Value | -- | -- | -48.75 | -28.67 | -19.54 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -11.83 | -46.65 | -14.41 |
| Net Margin
| -- | -- | -13.96 | -- | -- |
| Return on equity
| -- | -- | -33.52 | -68.45 | -17.15 |
| Return on Capital
| -- | -- | -- | -51.56 | -14.33 |
| Return on Assets
| -- | -- | -13.68 | -42.20 | -11.71 |
| Debt to Equity (x)
| -- | -- | 0.40 | 0.57 | 0.20 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
-51.56
|
-14.33
|
-26.78
|
-10.87
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-33.52
Lower than Peers by 38.46
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-33.52
|
-68.45
|
-17.15
|
-31.55
|
-12.64
|
|
Peer Median
|
4.94
|
--
|
--
|
--
|
--
|
ROA
-13.68
Lower than Peers by 16.13
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-13.68
|
-42.20
|
-11.71
|
-22.45
|
-9.34
|
|
Peer Median
|
2.45
|
--
|
--
|
--
|
--
|
EBIT Margin
-11.83
Lower than Peers by 20.30
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-11.83
|
-46.65
|
-14.41
|
-34.43
|
-18.23
|
|
Peer Median
|
8.47
|
--
|
--
|
--
|
--
|
Net Margin
-13.96
Lower than Peers by 18.64
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-13.96
|
-44.38
|
-15.20
|
-34.96
|
-16.51
|
|
Peer Median
|
4.68
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-3.16
Lower than Peers by 11.64
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-3.16
|
-0.02
|
0.11
|
0.11
|
-0.02
|
|
Peer Median
|
8.49
|
--
|
--
|
--
|
--
|
EBIT Growth
77.09
Higher than Peers by 66.45
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
77.09
|
-218.64
|
53.45
|
-88.72
|
-154.00
|
|
Peer Median
|
10.65
|
--
|
--
|
--
|
--
|
Net Profit Growth
71.51
Higher than Peers by 57.96
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
71.51
|
-187.43
|
51.65
|
-135.09
|
-311.76
|
|
Peer Median
|
13.55
|
--
|
--
|
--
|
--
|
EPS Growth
72.02
Higher than Peers by 51.51
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
72.02
|
-1.81
|
0.54
|
-1.23
|
-3.02
|
|
Peer Median
|
20.51
|
--
|
--
|
--
|
--
|
Book Value Growth
-23.60
Lower than Peers by 30.60
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-23.60
|
--
|
--
|
--
|
--
|
|
Peer Median
|
7.01
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.40
Higher than Peers by 0.00
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
0.40
|
0.57
|
0.20
|
0.19
|
0.16
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
0.02
|
0.02
|
0.02
|
0.02
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.21
Lower than Peers by 0.61
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
2.21
|
2.49
|
1.82
|
2.01
|
2.00
|
|
Peer Median
|
2.83
|
--
|
--
|
--
|
--
|
Quick Ratio
1.98
Lower than Peers by 0.07
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
1.98
|
2.26
|
1.65
|
1.87
|
1.85
|
|
Peer Median
|
2.05
|
--
|
--
|
--
|
--
|
Interest Coverage
-5.82
Lower than Peers by 10.78
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-5.82
|
-36.63
|
-43.11
|
-89.41
|
-38.66
|
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
13.58
Lower than Peers by 2.88
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
13.58
|
13.98
|
14.47
|
15.18
|
14.98
|
|
Peer Median
|
16.46
|
--
|
--
|
--
|
--
|
Asset Turnover
0.98
Higher than Peers by 0.48
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
0.98
|
0.95
|
0.77
|
0.64
|
0.57
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
52.38
|
51.35
|
52.35
|
54.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
42.80
|
35.84
|
32.55
|
36.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
45.90
|
42.07
|
42.22
|
52.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
49.29
|
45.12
|
42.68
|
38.97
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
-1.57
|
-9.81
|
-6.26
|
-16.97
|
|
Peer Median
|
44.46
|
--
|
--
|
--
|
--
|
Price / Book Value
1.00
Lower than Peers by 2.79
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
1.00
|
1.56
|
1.78
|
2.10
|
2.15
|
|
Peer Median
|
3.79
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-23.47
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
-23.47
|
-1.92
|
-21.63
|
-8.41
|
-28.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
302
Lower than Peers by 238
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Jun-23
|
|---|---|---|---|---|---|
|
Myriad Genetics (MYGN)
|
302
|
--
|
--
|
--
|
--
|
|
Peer Median
|
540
|
--
|
--
|
--
|
--
|